TTR and amyloidosis: In siRNA-based therapeutics, patisiran (Onpattro) became the first FDA-approved siRNA drug in 2018, targeting TTR mRNA to treat hereditary transthyretin-mediated amyloidosis (hATTR) by reducing toxic protein accumulation [195,248].